




Instance: composition-en-91532a0bac4066c0d200269dda7e0b3f
InstanceOf: CompositionUvEpi
Title: "Composition for vipdomet Package Leaflet"
Description:  "Composition for vipdomet Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc78593d9066d75b8d054a2b6ec43df97)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vipdomet"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Vipdomet is and what it is used for  </li>
<li>What you need to know before you take Vipdomet </li>
<li>How to take Vipdomet </li>
<li>Possible side effects  </li>
<li>How to store Vipdomet </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vipdomet is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vipdomet is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Vipdomet is 
Vipdomet contains two different medicines called alogliptin and metformin in one tablet:</p>
<ul>
<li>alogliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 
inhibitors). Alogliptin works to increase the levels of insulin in the body after a meal and 
decrease the amount of sugar in the body.  </li>
<li>metformin belongs to a group of medicines called biguanides which also help to lower blood 
sugar by lowering the amount of sugar made in the liver and helping insulin to work more 
effectively. </li>
</ul>
<p>Both of these groups of medicines are  oral anti-diabetics . </p>
<p>What Vipdomet is used for 
Vipdomet is used to lower blood sugar levels in adults with type 2 diabetes. Type 2 diabetes is also 
called non-insulin-dependent diabetes mellitus or NIDDM. </p>
<p>Vipdomet is taken when your blood sugar cannot be adequately controlled by diet, exercise and other 
anti-diabetic medicines such as metformin alone; insulin alone; or metformin and pioglitazone taken 
together.  </p>
<p>If you are already taking both alogliptin and metformin as single tablets, Vipdomet can replace them in 
one tablet. </p>
<p>It is important that you continue to follow the advice on diet and exercise that your nurse or doctor has 
given you. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vipdomet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vipdomet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Vipdomet 
- if you are allergic to alogliptin, metformin or any of the other ingredients of this medicine 
(listed in section 6). 
- if you have had a serious allergic reaction to any other similar medicines that you take to control 
your blood sugar. Symptoms of a serious allergic reaction may include; rash, raised red patches 
on your skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty in 
breathing or swallowing. Additional symptoms may include general itching and feeling of heat 
especially affecting the scalp, mouth, throat, palms of hands and soles of feet (Stevens-Johnson 
syndrome). 
- if you have severely reduced kidney function 
- if you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood 
glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactate acidosis (see  Risk of lactic 
acidosis  below) or ketoacidosis. Ketoacidosis is a condition in which substances called 'ketone 
bodies' accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include 
stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual fruity 
smell.<br />
- if you have a severe infection or are seriously dehydrated (have lost a lot of water from your 
body) 
- if you recently had a heart attack or have severe circulatory problems including shock 
- if you have severe breathing difficulties<br />
- if you have liver disease 
- if you drink alcohol excessively (either every day or in large quantities only from time to time) </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Vipdomet :</p>
<ul>
<li>if you have type 1 diabetes (your body does not produce insulin). </li>
<li>if you are taking Vipdomet with insulin or a thiazolidinedione. Your doctor may want to reduce 
your dose of insulin or a thiazolidinedione when you take it together with Vipdomet in order to 
avoid too low blood sugar (hypoglycaemia). </li>
<li>if you are taking another medicine for diabetes that contains a  sulphonylurea , you should not 
start taking Vipdomet. </li>
<li>if you have or have had a disease of the pancreas. </li>
<li>in case of symptoms suggestive of liver injury during Vipdomet therapy. </li>
</ul>
<p>Contact your doctor if you encounter blistering of the skin, as it may be a sign for a condition called 
bullous pemphigoid. Your doctor may ask you to stop alogliptin. </p>
<p>Risk of lactic acidosis 
Vipdomet may cause a very rare, but very serious side effect called lactic acidosis, particularly if your 
kidneys are not working properly. The risk of developing lactic acidosis is also increased with 
uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further 
information below), liver problems and any medical conditions in which a part of the body has a 
reduced supply of oxygen (such as acute severe heart disease). If any of the above apply to you, talk to 
your doctor for further instructions. </p>
<p>Stop taking Vipdomet for a short time if you have a condition that may be associated with 
dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to 
heat or if you drink less fluid than normal. Talk to your doctor for further instructions. </p>
<p>Stop taking Vipdomet and contact a doctor or the nearest hospital immediately if you experience 
some of the symptoms of lactic acidosis, as this condition may lead to coma. 
Lactic acidosis is a medical emergency and must be treated in a hospital. If lactic acidosis is suspected, 
seek medical attention from a doctor or a hospital. 
Symptoms of lactic acidosis include:</p>
<ul>
<li>vomiting </li>
<li>stomach ache (abdominal pain) </li>
<li>muscle cramps </li>
<li>a general feeling of not being well with severe tiredness </li>
<li>difficulty in breathing </li>
<li>reduced body temperature and heartbeat. </li>
</ul>
<p>If you need to have major surgery you must stop taking Vipdomet during and for some time before 
and after the procedure. Your doctor will decide when you must stop and when to restart your 
treatment with Vipdomet. </p>
<p>During treatment with Vipdomet, your doctor will check your kidney function at least once a year or 
more frequently if you are elderly and/or if have worsening kidney function </p>
<p>Children and adolescents 
Vipdomet is not recommended for children and adolescents under 18 years due to the lack of data in 
these patients.  </p>
<p>Other medicines and Vipdomet 
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for 
example in the context of an X-ray or scan, you must stop taking Vipdomet before or at the time of the 
injection. Your doctor will decide when you must stop and when to restart your treatment with 
Vipdomet. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may 
need to adjust the dose of Vipdomet. It is especially important to mention the following:</p>
<ul>
<li>hydrocortisone and prednisolone (corticosteroids), used to treat diseases that involve 
inflammation like asthma and arthritis  </li>
<li>cimetidine, used to treat stomach problems </li>
<li>bronchodilators (beta-2 agonists), used to treat asthma </li>
<li>medicines which increase urine production (diuretics)  </li>
<li>medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as 
ibuprofen and celecoxib),  </li>
<li>certain medicines used for the treatment of high blood pressure (ACE inhibitors  and 
angiotensin II receptor antagonists)  </li>
<li>medicines containing alcohol. </li>
</ul>
<p>Vipdomet with alcohol 
Avoid excessive alcohol intake while taking Vipdomet since this may increase the risk of lactic 
acidosis - see section  Warnings and precautions . </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. You should not use Vipdomet if you 
are pregnant. </p>
<p>Vipdomet is not recommended during breast-feeding since metformin passes into breast milk. </p>
<p>Driving and using machines 
Vipdomet is not known to affect your ability to drive and use machines. Taking Vipdomet in 
combination with medicines called pioglitazone or insulin can cause too low blood sugar levels 
(hypoglycaemia), which may affect your ability to drive and use machines.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vipdomet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vipdomet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. 
Your doctor will tell you exactly how much Vipdomet you need to take. The amount of Vipdomet will 
vary depending on your condition and the doses you currently take of metformin alone, metformin in 
combination with pioglitazone, insulin and/or individual tablets of alogliptin and metformin.  </p>
<p>The recommended dose is one tablet twice a day. If you have reduced kidney function, your doctor 
may prescribe a lower dose, which may need to be given as separate tablets of alogliptin and 
metformin. </p>
<p>Swallow your tablet(s) whole with water. You should take this medicine with food to reduce your 
chance of an upset stomach. </p>
<p>If you take more Vipdomet than you should 
If you take more tablets than you should, or if someone else or a child takes your medicine, contact or 
go to your nearest emergency centre straight away. Take this leaflet or some tablets with you so that 
your doctor knows exactly what you have taken.  </p>
<p>If you forget to take Vipdomet 
If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up 
for a forgotten dose. </p>
<p>If you stop taking Vipdomet 
Do not stop taking Vipdomet without consulting your doctor first. Your blood sugar levels may 
increase when you stop taking Vipdomet. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>STOP taking Vipdomet and contact a doctor or the nearest hospital immediately if you notice 
any of the symptoms of the following serious side effects: </p>
<p>Very rare (may affect up to 1 in 10,000 people):</p>
<ul>
<li>Lactic acidosis (a build-up of lactic acid in the blood) is a very serious side effect that may lead 
to coma. For symptoms see section  Warnings and precautions .  </li>
</ul>
<p>Not known (frequency cannot be estimated from the available data):</p>
<ul>
<li>An allergic reaction. The symptoms may include: a rash, hives, swallowing or breathing 
problems, swelling of your lips, face, throat or tongue and feeling faint. </li>
<li>A severe allergic reaction: skin lesions or spots on your skin that can progress to a sore 
surrounded by pale or red rings, blistering and/or peeling of the skin possibly with symptoms 
such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy 
eyes and mouth sores (Stevens-Johnson syndrome and Erythema multiforme). </li>
<li>Severe and persistent pain in the abdomen (stomach area) which might reach through to your 
back as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis).  </li>
</ul>
<p>You should also discuss with your doctor if you experience the following side effects:  </p>
<p>Very common (may affect more than 1 in 10 people):</p>
<ul>
<li>Stomach ache </li>
<li>Diarrhoea  </li>
<li>Loss of appetite </li>
<li>Feeling sick  </li>
<li>
<p>Being sick. 
Common (may affect up to 1 in 10 people):</p>
</li>
<li>
<p>Symptoms of low blood sugar (hypoglycaemia) may occur when Vipdomet is taken in 
combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide). 
Symptoms may include: trembling, sweating, anxiety, blurred vision, tingling lips, paleness, 
mood change or feeling confused. Your blood sugar could fall below the normal level, but can 
be increased again by taking sugar. It is recommended that you carry some sugar lumps, sweets, 
biscuits or sugary fruit juice. </p>
</li>
<li>Cold symptoms such as sore throat, stuffy or blocked nose, feeling tired, fever, chills, dry cough </li>
<li>Rash  </li>
<li>Itchy skin with or without hives </li>
<li>Headache </li>
<li>Indigestion, heartburn </li>
<li>Vomiting and/or diarrhoea </li>
<li>Metallic taste </li>
<li>Decreased or low vitamin B12 levels in the blood (symptoms may include extreme tiredness 
(fatigue), a sore and red tongue (glossitis), pins and needles (paraesthesia) or pale or yellow 
skin).  Your doctor may arrange some tests to find out the cause of your symptoms because 
some of these may also be caused by diabetes or due to other unrelated health problems </li>
</ul>
<p>Very rare:</p>
<ul>
<li>Liver problems (hepatitis or liver function test abnormalities) </li>
<li>Erythema (redness of skin). </li>
</ul>
<p>Not known:</p>
<ul>
<li>Liver problems such as nausea or vomiting, stomach pain, unusual or unexplained tiredness, 
loss of appetite, dark urine or yellowing of your skin or the whites of your eyes. </li>
<li>Inflammation of the connective tissue within the kidneys (interstitial nephritis) </li>
<li>Blistering of the skin (bullous pemphigoid). </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vipdomet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vipdomet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month. </p>
<p>This medicinal product does not require any special storage conditions.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Vipdomet contains<br />
- The active substances are alogliptin and metformin hydrochloride. 
Each 12.5 mg/850 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin 
and 850 mg metformin hydrochloride. 
Each 12.5 mg/1,000 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg 
alogliptin and 1,000 mg metformin hydrochloride. 
- The other ingredients are mannitol, microcrystalline cellulose, povidone K30, 
crospovidone Type A, magnesium stearate, hypromellose, talc, titanium dioxide (E171) and 
yellow iron oxide (E172). </p>
<p>What Vipdomet looks like and contents of the pack 
- Vipdomet 12.5 mg/850 mg film-coated tablets (tablets) are light yellow, oblong (approximately 
21.0 mm long by 10.1 mm wide), biconvex, film-coated tablets with  12.5/850  debossed on 
one side and  322M  debossed on the other side. 
- Vipdomet 12.5 mg/1,000 mg film-coated tablets (tablets) are pale yellow, oblong 
(approximately 22.3 mm long by 10.7 mm wide), biconvex, film-coated tablets with 
 12.5/1000  debossed on one side and  322M  debossed on the other side.  </p>
<p>Vipdomet is available in blister packs containing 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196, 
200 tablets and in multipacks comprising 2 packs each containing 98 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Takeda Pharma A/S 
Delta Park 2665 Vallensbaek Strand 
Denmark  </p>
<p>Manufacturer 
Takeda Ireland Limited 
Bray Business Park 
Kilruddery 
Co. Wicklow 
Ireland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Takeda Belgium NV 
Tel/T l: +32 2 464 06 medinfoEMEA@takeda.com </p>
<p>Lietuva 
Takeda, UAB 
Tel: +370 521 09 medinfoEMEA@takeda.com </p>
<p>.: +359 2 958 27 medinfoEMEA@takeda.com </p>
<p>Luxembourg/Luxemburg 
Takeda Belgium NV 
Tel/T l: +32 2 464 06 medinfoEMEA@takeda.com  </p>
<p>esk  republika 
Takeda Pharmaceuticals Czech Republic s.r.o. 
Tel: +420 234 722 medinfoEMEA@takeda.com </p>
<p>Magyarorsz g 
Takeda Pharma Kft. 
Tel: +36 1 270 7medinfoEMEA@takeda.com 
Danmark 
Takeda Pharma A/S 
Tlf: +45 46 77 10 medinfoEMEA@takeda.com </p>
<p>Malta 
Takeda HELLAS S.A. 
Tel: +30 210 6387medinfoEMEA@takeda.com </p>
<p>Deutschland 
Takeda GmbH 
Tel: +49 (0)800 825 3medinfoEMEA@takeda.com<br />
Nederland 
Takeda Nederland B.V. 
Tel: +31 20 203 5medinfoEMEA@takeda.com </p>
<p>Eesti 
Takeda Pharma AS 
Tel: +372 6177 medinfoEMEA@takeda.com </p>
<p>Norge 
Takeda AS 
Tlf: +47 800 800 medinfoEMEA@takeda.com </p>
<p>Takeda    . . 
 : +30 210 6387medinfoEMEA@takeda.com  </p>
<p>sterreich 
Takeda Pharma Ges. m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com  </p>
<p>Espa a 
Laboratorios Menarini, S.A 
Tel: +34 934 628 info@menarini.es </p>
<p>Polska 
Takeda Pharma Sp. z o.o. 
tel: +48223062medinfoEMEA@takeda.com  </p>
<p>France 
Takeda France SAS 
Tel: + 33 1 40 67 33 medinfoEMEA@takeda.com </p>
<p>Portugal 
Tecnimede - Sociedade T cnico-Medicinal, S.A 
Tel: +351 21 041 41 dmed.fv@tecnimede.pt  </p>
<p>Hrvatska 
Takeda Pharmaceuticals Croatia d.o.o 
Tel: +385 1 377 88 medinfoEMEA@takeda.com 
Rom nia 
Takeda Pharmaceuticals SRL 
Tel: +40 21 335 03 medinfoEMEA@takeda.com </p>
<p>Ireland 
Takeda Products Ireland Ltd 
Tel: 1800 937 medinfoEMEA@takeda.com </p>
<p>Slovenija 
Takeda Pharmaceuticals farmacevtska dru ba d.o.o.<br />
Tel: +386 (0) 59 082 medinfoEMEA@takeda.com </p>
<p>sland 
Vistor hf. 
S mi: +354 535 7medinfoEMEA@takeda.com </p>
<p>Slovensk  republika 
Takeda Pharmaceuticals Slovakia s.r.o. 
Tel: +421 (2) 20 602 medinfoEMEA@takeda.com </p>
<p>Italia 
Takeda Italia S.p.A. 
Tel: +39 06 502medinfoEMEA@takeda.com </p>
<p>Suomi/Finland 
Takeda Oy 
Puh/Tel: 0800 774 medinfoEMEA@takeda.com </p>
<p>Takeda    . . 
 : +30 210 6387medinfoEMEA@takeda.com </p>
<p>Sverige 
Takeda Pharma AB 
Tel: 020 795 medinfoEMEA@takeda.com </p>
<p>Latvija 
Takeda Latvia SIA 
Tel: +371 67840medinfoEMEA@takeda.com </p>
<p>United Kingdom (Northern Ireland) 
Takeda UK Ltd 
Tel: +44 (0) 2830 640 medinfoEMEA@takeda.com </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-91532a0bac4066c0d200269dda7e0b3f
InstanceOf: CompositionUvEpi
Title: "Composition for vipdomet Package Leaflet"
Description:  "Composition for vipdomet Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc78593d9066d75b8d054a2b6ec43df97)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vipdomet"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at tage Vipdomet </li>
<li>Sådan skal du tage Vipdomet </li>
<li>Bivirkninger  </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger. </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vipdomet is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vipdomet is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning 
Vipdomet indeholder to forskellige lægemidler, alogliptin og metformin, i én tablet:</p>
<ul>
<li>alogliptin tilhører en gruppe af lægemidler, der kaldes DPP-4-hæmmere 
(dipeptidyl peptidase-4-hæmmere). Formålet med alogliptin er at øge insulinniveauet i kroppen 
efter et måltid og sænke mængden af sukker i kroppen.  </li>
<li>metformin tilhører en gruppe af lægemidler, som kaldes biguanider, og som også hjælper med at 
sænke blodets sukkerindhold ved at sænke mængden af sukker, der produceres i leveren, og får 
insulinen til at virke mere effektivt. </li>
</ul>
<p>Begge disse lægemidler kaldes orale antidiabetika (diabetesmedicin, der indtages gennem munden). </p>
<p>Anvendelse 
Vipdomet sænker blodsukkeret hos voksne med type 2-diabetes. Type 2-diabetes kaldes også 
ikke-insulinkrævende diabetes mellitus eller gammelmandssukkersyge. </p>
<p>Du kan tage Vipdomet, hvis dit blodsukker ikke kan styres godt nok gennem kost, motion og andre 
antidiabetika såsom metformin taget alene, insulin taget alene eller metformin og pioglitazon taget 
samtidigt.  </p>
<p>Hvis du allerede tager både alogliptin og metformin som separate tabletter, kan Vipdomet erstatte dem 
begge. </p>
<p>Det er vigtigt, at du bliver ved med at følge de råd om kost og motion, som din læge eller 
sygeplejerske har givet dig. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vipdomet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vipdomet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Vipdomet 
- hvis du er allergisk over for alogliptin, metformin eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i punkt 6).<br />
- hvis du har haft en alvorlig allergisk reaktion over for andre lignende lægemidler, som du tager 
for at styre dit blodsukker. Tegn på en alvorlig allergisk reaktion kan være udslæt, hævede røde 
områder på huden (nældefeber) og hævelse af ansigtet, læber, tunge eller svælg, som kan gøre 
det svært for dig at trække vejret eller synke. Andre symptomer kan være kløe, en følelse af 
varme især i hovedbund, mund, svælg, håndfladerne og fodsålerne (Stevens-Johnsons 
syndrom).<br />
- hvis du har alvorligt nedsat nyrefunktion. 
- hvis du har dårligt kontrolleret diabetes, der eksempelvis er ledsaget af alvorlig hyperglykæmi 
(højt blodsukker), kvalme, opkastning, diarré, hurtigt vægttab, laktatacidose (se "Risiko for 
laktatacidose" nedenfor) eller ketoacidose. Ketoacidose er en tilstand, hvor såkaldte ketonstoffer 
ophobes i blodet, hvilket kan føre til diabetisk prækoma. Symptomerne omfatter mavesmerter, 
hurtig og dyb vejrtrækning og søvnighed, og din ånde kan få en usædvanlig frugtagtig lugt. 
- hvis du har en svær infektion eller alvorlig væskemangel (er stærkt dehydreret).<br />
- hvis du for nyligt har haft et hjerteanfald eller har svære kredsløbsproblemer, herunder shock.<br />
- hvis du har alvorligt åndedrætsbesvær.<br />
- hvis du har en leversygdom.<br />
- hvis du har et overdrevet alkoholforbrug (enten drikker hver dag eller drikker store mængder en 
gang imellem). </p>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen eller apotekspersonalet, før du tager Vipdomet:</p>
<ul>
<li>hvis du har type 1-diabetes (din krop kan ikke producere insulin).  </li>
<li>hvis du tager Vipdomet sammen med insulin eller et thiazolidindion. Din læge vil muligvis 
nedsætte din insulin- eller thiazolidindion-dosis, hvis du også tager Vipdomet, så du undgår at 
få for lavt blodsukker (hypoglykæmi).  </li>
<li>hvis du tager et andet lægemiddel mod diabetes, som indeholder et såkaldt sulfonylurinstof. I så 
fald må du ikke begynde at tage Vipdomet.  </li>
<li>hvis du har eller har haft sygdom i bugspytkirtlen. </li>
<li>hvis du får symptomer, der tyder på en leverskade, mens du tager Vipdomet. </li>
</ul>
<p>Kontakt lægen, hvis du får blærer på huden, da det kan være tegn på en sygdom, der hedder bulløs 
pemfigoid. Din læge vil muligvis bede dig om at holde op med at tage alogliptin. </p>
<p>Risiko for laktatacidose 
Vipdomet kan forårsage en meget sjælden, men meget alvorlig bivirkning, som kaldes laktatacidose, 
især hvis dine nyrer ikke fungerer korrekt. Risikoen for at udvikle laktatacidose er også forhøjet ved 
dårligt kontrolleret diabetes, alvorlige infektioner, længerevarende faste eller alkoholindtagelse, 
dehydrering (væskemangel, se yderligere oplysninger nedenfor), leverproblemer og enhver tilstand 
med nedsat iltforsyning til en legemsdel (såsom akut alvorlig hjertesygdom).<br />
Kontakt lægen for at få yderligere vejledning, hvis noget af ovennævnte gælder for dig. </p>
<p>Stop med at tage Vipdomet i en kort periode, hvis du har en tilstand, som kan være forbundet 
med dehydrering (betydeligt tab af kropsvæsker), såsom alvorlig opkastning, diarré, feber, udsættelse 
for varme eller indtagelse af mindre væske end normalt. Kontakt lægen for at få yderligere rådgivning. </p>
<p>Stop med at tage Vipdomet og kontakt omgående læge eller nærmeste hospital, hvis du får et 
eller flere af nedenstående symptomer på laktatacidose, da denne tilstand kan føre til koma.<br />
Laktatacidose er en alvorlig tilstand, der skal behandles på et hospital. Søg læge ved mistanke om 
laktatacidose. 
Symptomerne på laktatacidose omfatter:</p>
<ul>
<li>opkastning </li>
<li>mavesmerter </li>
<li>muskelkramper </li>
<li>almen utilpashed med udpræget træthed </li>
<li>vejrtrækningsbesvær </li>
<li>nedsat kropstemperatur og langsommere puls.  </li>
</ul>
<p>Hvis du skal have en større operation, skal du stoppe med at tage Vipdomet under indgrebet og i 
nogen tid herefter. Lægen vil beslutte, hvornår du skal stoppe behandlingen med Vipdomet, og 
hvornår du kan genoptage den igen. </p>
<p>Under behandlingen med Vipdomet vil lægen kontrollere din nyrefunktion mindst en gang om året 
eller hyppigere, hvis du er ældre, og/eller hvis din nyrefunktion bliver dårligere. </p>
<p>Børn og unge 
Vipdomet anbefales ikke til børn og unge under 18 år, da der ikke foreligger tilstrækkelige data for 
denne aldersgruppe.  </p>
<p>Brug af anden medicin sammen med Vipdomet 
Hvis du skal have sprøjtet et kontrastmiddel, som indeholder jod, ind i dit blod, for eksempel i 
forbindelse med en røntgenundersøgelse eller scanning, skal du stoppe med at tage Vipdomet forud for 
eller på tidspunktet for injektionen. Lægen vil beslutte, hvornår du skal stoppe behandlingen med 
Vipdomet, og hvornår du kan genoptage den igen. 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin for nylig har taget anden 
medicin eller planlægger at tage anden medicin. Du skal eventuelt have kontrolleret dit blodsukker 
eller din nyrefunktion hyppigere, eller lægen kan ændre din dosis af Vipdomet. Det er især vigtigt, at 
du nævner følgende:</p>
<ul>
<li>hydrokortison og prednisolon (kortikosteroider), som bruges til at behandle sygdomme, hvor der 
er en betændelsestilstand, f.eks. astma og gigt  </li>
<li>cimetidin, som bruges til at behandle maveproblemer  </li>
<li>bronkodilatatorer (beta-2-antagonister), som bruges til at behandle astma </li>
<li>vanddrivende lægemidler (diuretika) </li>
<li>lægemidler mod smerter og betændelseslignende tilstande (NSAID’er og COX-2-hæmmere, 
såsom ibuprofen og celecoxib) </li>
<li>visse lægemidler, der nedsætter blodtrykket (ACE-hæmmere og angiotensin 
II-receptorantagonister) </li>
<li>lægemidler, der indeholder alkolhol.  </li>
</ul>
<p>Brug af Vipdomet sammen med alkohol 
Du skal undgå at indtage store mængder alkohol, mens du er i behandling med Vipdomet, da det kan 
øge risikoen for laktatacidose (se afsnittet "Advarsler og forsigtighedsregler"). </p>
<p>Graviditet og amning<br />
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. Du bør ikke tage 
Vipdomet, hvis du er gravid. </p>
<p>Det frarådes, at du tager Vipdomet, hvis du ammer, da indholdsstoffet metformin udskilles i 
modermælken. </p>
<p>Trafik- og arbejdssikkerhed 
Vipdomet har ikke nogen kendt virkning på evnen til at køre bil og betjene maskiner. Hvis du tager 
Vipdomet samtidig med lægemidlerne pioglitazon eller insulin, kan du få for lavt blodsukker 
(hypoglykæmi), hvilket kan påvirke din evne til at køre bil og betjene maskiner.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vipdomet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vipdomet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens, eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen, eller apotekspersonalet. </p>
<p>Lægen vil fortælle dig, præcis hvor mange Vipdomet-tabletter du skal tage. Antallet afhænger af din 
tilstand, og af hvor stor en dosis du i forvejen tager af metformin alene eller kombineret med 
pioglitazon, af insulin og/eller separate tabletter med alogliptin og metformin.  </p>
<p>Den anbefalede dosis er 1 tablet to gange dagligt. Hvis du har nedsat nyrefunktion, vil lægen eventuelt 
ordinere en lavere dosis, som eventuelt skal gives som separate tabletter med alogliptin og metformin. </p>
<p>Synk tabletten hel sammen med vand. Du bør tage Vipdomet sammen med et måltid for at mindske 
risikoen for maveproblemer. </p>
<p>Hvis du har taget for meget Vipdomet 
Hvis du har taget flere tabletter, end du skulle, eller hvis en anden person, f.eks. et barn, tager dine 
tabletter, skal du kontakte læge eller søge til den nærmeste skadestue med det samme. Tag denne 
indlægsseddel eller nogle tabletter med, så lægen nøjagtigt ved, hvad der er indtaget.  </p>
<p>Hvis du har glemt at tage Vipdomet 
Hvis du har glemt at tage en dosis, skal du tage den, så snart du kommer i tanke om det. Du må ikke 
tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Vipdomet 
Hold ikke op med at tage Vipdomet uden at tale med din læge først. Dit blodsukker kan blive højere, 
når du holder op med at tage Vipdomet. </p>
<p>Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>STOP med at tage Vipdomet, og kontakt lægen eller det nærmeste hospital med det samme, hvis 
du får nogen af symptomerne på de følgende alvorlige bivirkninger:  </p>
<p>Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 personer):</p>
<ul>
<li>Laktatacidose (ophobning af mælkesyre i blodet) er en meget alvorlig bivirkning, som kan føre 
til koma. For symptomer se punktet “Advarsler og forsigtighedsregler".  </li>
</ul>
<p>Bivirkninger med ukendt hyppighed (hyppigheden kan ikke bestemmes ud fra de foreliggende 
data):</p>
<ul>
<li>Allergisk reaktion. Tegnene kan være udslæt, nældefeber, synke- eller åndedrætsbesvær, 
hævelse af læber, ansigt, svælg eller tunge og besvimelsesfornemmelse.  </li>
<li>En alvorlig overfølsomhedsreaktion: hudlæsioner eller pletter på huden, der kan udvikle sig 
til et sår omgivet af blege eller røde ringe, blæredannelse og/eller afskalning af huden eventuelt 
med symptomer som kløe, feber, generel utilpashed, smertende led, synsforstyrrelser, 
brændende smertefuld eller kløende øjne og sår i munden (Stevens-Johnsons syndrome og 
erythema multiforme).  </li>
<li>Stærke og vedvarende smerter i maven, som kan stråle ud i ryggen, samt kvalme og 
opkastning. Det kan være tegn på betændelse i bugspytkirtlen (pancreatitis).  </li>
</ul>
<p>Du skal også fortælle din læge, hvis du får følgende bivirkninger:  </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer):</p>
<ul>
<li>Mavesmerter  </li>
<li>Diarré  </li>
<li>Appetitløshed  </li>
<li>Kvalme  </li>
<li>Opkastning.  </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer):</p>
<ul>
<li>Tegn på lavt blodsukker (hypoglykæmi), som kan opstå, hvis Vipdomet tages i kombination 
med insulin eller sulfonylurinstof (f.eks. glipizid, tolbutamid eller glibenclamid). Tegnene kan 
være: rysten, svedtendens, angst, sløret syn, prikkende fornemmelse i læber, bleghed, 
humørsvingninger eller forvirring. Blodsukkeret kan falde til under det normale niveau, men 
kan bringes til at stige igen, hvis du indtager sukker. Det anbefales, at du altid medbringer lidt 
sukkerknalder, slik, kiks eller sukkerholdig frugtjuice. </li>
<li>Forkølelsessymptomer som ondt i halsen, tilstoppet næse, træthed, feber, kulderystelser og tør 
hoste </li>
<li>Udslæt  </li>
<li>Kløende hud med eller uden nældefeber </li>
<li>Hovedpine </li>
<li>Fordøjelsesbesvær, opstød </li>
<li>Opkastning og/eller diarré </li>
<li>Metalsmag i munden </li>
<li>Nedsat eller lavt B12-vitaminniveau i blodet (symptomerne kan omfatte ekstrem træthed 
(udmattelse), øm og rød tunge (glossitis), en prikkende eller snurrende fornemmelse (paræstesi) 
eller bleg eller gullig hud). Lægen vil måske tage prøver for at finde årsagen til dine symptomer, 
da nogle af disse også kan skyldes diabetes eller andre helbredsproblemer uden forbindelse 
hermed. </li>
</ul>
<p>Meget sjældne bivirkninger:</p>
<ul>
<li>Problemer med leveren (hepatitis eller unormale leverfunktionstest) </li>
<li>Erytem (hudrødme).  </li>
</ul>
<p>Bivirkninger med ukendt hyppighed:</p>
<ul>
<li>Leverproblemer, der viser sig som kvalme, opkastning, mavesmerter, usædvanlig eller 
uforklarlig træthed, manglende appetit, mørkfarvet urin eller gulfarvning af huden eller det 
hvide i øjnene.  </li>
<li>Betændelse i bindevævet i nyrerne (interstitiel nefritis). </li>
<li>Blærer på huden (bulløs pemfigoid). </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apoteketspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vipdomet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vipdomet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisterkortet efter 'EXP'. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.  </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vipdomet indeholder 
- Aktive stoffer: alogliptin og metforminhydrochlorid. 
Hver 12,5 mg/850 mg filmovertrukken tablet indeholder alogliptinbenzoat svarende til 12,5 mg 
alogliptin og 850 mg metforminhydrochlorid. 
Hver 12,5 mg/1.000 mg filmovertrukken tablet indeholder alogliptinbenzoat svarende til 12,5 mg 
alogliptin og 1.000 mg metforminhydrochlorid. 
- Øvrige indholdsstoffer: mannitol, mikrokrystallinsk cellulose, povidon K30, 
crospovidon type A, magnesiumstearat, hypromellose, talkum, titandioxid (E171) og gul 
jernoxid (E172). </p>
<p>Udseende og pakningsstørrelser 
- Vipdomet 12,5 mg/850 mg filmovertrukne tabletter (tabletter) er lysegule, aflange (ca. 21,0 x 
10,1 mm), bikonvekse filmovertrukne tabletter, der er præget med "12.5/850" på den ene side 
og "322M" på den anden side. 
- Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter (tabletter) er svagt gule, aflange (ca. 
22,3 x 10,7 mm), bikonvekse filmovertrukne tabletter, der er præget med "12.5/1000" på den 
ene side og "322M" på den anden side. </p>
<p>Vipdomet fås i blisterpakninger med 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196 eller 200 tabletter 
samt i multipakninger bestående af 2 pakninger med hver 98 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Takeda Pharma A/S 
Delta Park 2665 Vallensbæk Strand 
Danmark  </p>
<p>Fremstiller 
Takeda Ireland Limited 
Bray Business Park 
Kilruddery 
Co. Wicklow 
Irland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Takeda Belgium NV 
Tel/Tél: +32 2 464 06 medinfoEMEA@takeda.com </p>
<p>Lietuva 
Takeda, UAB 
Tel: +370 521 09 medinfoEMEA@takeda.com </p>
<p>България 
Такеда България ЕООД 
Тел.: +359 2 958 27 medinfoEMEA@takeda.com </p>
<p>Luxembourg/Luxemburg 
Takeda Belgium NV 
Tel/Tél: +32 2 464 06 medinfoEMEA@takeda.com  </p>
<p>Česká republika 
Takeda Pharmaceuticals Czech Republic s.r.o. 
Tel: +420 234 722 medinfoEMEA@takeda.com </p>
<p>Magyarország 
Takeda Pharma Kft. 
Tel: +36 1 270 7medinfoEMEA@takeda.com 
Danmark 
Takeda Pharma A/S 
Tlf: +45 46 77 10 medinfoEMEA@takeda.com </p>
<p>Malta 
Takeda HELLAS S.A. 
Tel: +30 210 6387medinfoEMEA@takeda.com </p>
<p>Deutschland 
Takeda GmbH 
Tel: +49 (0)800 825 3medinfoEMEA@takeda.com<br />
Nederland 
Takeda Nederland B.V. 
Tel: +31 20 203 5medinfoEMEA@takeda.com </p>
<p>Eesti 
Takeda Pharma AS 
Tel: +372 6177 medinfoEMEA@takeda.com </p>
<p>Norge 
Takeda AS 
Tlf: +47 800 800 medinfoEMEA@takeda.com </p>
<p>Ελλάδα 
Takeda ΕΛΛΑΣ Α.Ε. 
Τηλ: +30 210 6387medinfoEMEA@takeda.com  </p>
<p>Österreich 
Takeda Pharma Ges. m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com  </p>
<p>España 
Laboratorios Menarini, S.A 
Tel: +34 934 628 info@menarini.es </p>
<p>Polska 
Takeda Pharma Sp. z o.o. 
tel: +48223062medinfoEMEA@takeda.com  </p>
<p>France 
Takeda France SAS 
Tel: + 33 1 40 67 33 medinfoEMEA@takeda.com </p>
<p>Portugal 
Tecnimede - Sociedade Técnico-Medicinal, S.A 
Tel: +351 21 041 41 00<br />
dmed.fv@tecnimede.pt  </p>
<p>Hrvatska 
Takeda Pharmaceuticals Croatia d.o.o 
Tel: +385 1 377 88 medinfoEMEA@takeda.com 
România 
Takeda Pharmaceuticals SRL 
Tel: +40 21 335 03 medinfoEMEA@takeda.com </p>
<p>Ireland 
Takeda Products Ireland Ltd 
Tel: 1800 937 medinfoEMEA@takeda.com </p>
<p>Slovenija 
Takeda Pharmaceuticals farmacevtska družba d.o.o.<br />
Tel: +386 (0) 59 082 medinfoEMEA@takeda.com </p>
<p>Ísland 
Vistor hf. 
Sími: +354 535 7medinfoEMEA@takeda.com </p>
<p>Slovenská republika 
Takeda Pharmaceuticals Slovakia s.r.o. 
Tel: +421 (2) 20 602 medinfoEMEA@takeda.com </p>
<p>Italia 
Takeda Italia S.p.A. 
Tel: +39 06 502medinfoEMEA@takeda.com </p>
<p>Suomi/Finland 
Takeda Oy 
Puh/Tel: 0800 774 medinfoEMEA@takeda.com </p>
<p>Κύπρος 
Takeda ΕΛΛΑΣ Α.Ε. 
Τηλ: +30 210 6387medinfoEMEA@takeda.com </p>
<p>Sverige 
Takeda Pharma AB 
Tel: 020 795 medinfoEMEA@takeda.com </p>
<p>Latvija 
Takeda Latvia SIA 
Tel: +371 67840medinfoEMEA@takeda.com </p>
<p>United Kingdom (Northern Ireland) 
Takeda UK Ltd 
Tel: +44 (0) 2830 640 medinfoEMEA@takeda.com </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-91532a0bac4066c0d200269dda7e0b3f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vipdomet Package Leaflet for language en"
Description: "ePI document Bundle for vipdomet Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-91532a0bac4066c0d200269dda7e0b3f"
* entry[0].resource = composition-en-91532a0bac4066c0d200269dda7e0b3f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp91532a0bac4066c0d200269dda7e0b3f"
* entry[=].resource = mp91532a0bac4066c0d200269dda7e0b3f
                            
                    
Instance: bundlepackageleaflet-da-91532a0bac4066c0d200269dda7e0b3f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vipdomet Package Leaflet for language da"
Description: "ePI document Bundle for vipdomet Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-91532a0bac4066c0d200269dda7e0b3f"
* entry[0].resource = composition-da-91532a0bac4066c0d200269dda7e0b3f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp91532a0bac4066c0d200269dda7e0b3f"
* entry[=].resource = mp91532a0bac4066c0d200269dda7e0b3f
                            
                    



Instance: mp91532a0bac4066c0d200269dda7e0b3f
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product vipdomet"
Description: "vipdomet"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/843/001-026"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type 2 diabetes"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "vipdomet"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 91532a0bac4066c0d200269dda7e0b3fListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "vipdomet"

* status = #current
* mode = #working

* title = "List of all ePIs associated with vipdomet"

* subject = Reference(mpc78593d9066d75b8d054a2b6ec43df97)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#vipdomet "vipdomet"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-91532a0bac4066c0d200269dda7e0b3f) // vipdomet en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-91532a0bac4066c0d200269dda7e0b3f) // vipdomet da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-91532a0bac4066c0d200269dda7e0b3f
InstanceOf: List

* insert 91532a0bac4066c0d200269dda7e0b3fListRuleset
    